Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
P 1 (1)

Trial Status

Enrolling By Invitation1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07354139Not ApplicableRecruiting

Using Non-invasive Brain Stimulation to Explore Potential Treatments to Reduce Speech Errors in Adults Who Stutter

NCT06368726Phase 1Enrolling By Invitation

Result of tDCS in ASD Children With Comorbidities Like PANDAS, Rare Genetic Diseases or Autoimmune Disorders

Showing all 2 trials

Research Network

Activity Timeline